Drugs / FCN-338
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04682808 | May 2021 → Apr 2024 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Fochon Pharmaceuticals, Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06858618 | Aug 2023 → Dec 2026 expected | — | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCN-338 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682808 ↗ |
| Route | Oral | “FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.” NCT04682808 ↗ |